{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:42:55Z","timestamp":1786117375293,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["archives-pmr.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Physical Medicine and Rehabilitation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.apmr.2026.02.498","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:19:47Z","timestamp":1773249587000},"page":"2227-2236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 Receptor Agonists as Pharmacologic Treatment for Obesity After Spinal Cord Injury: Clinical Considerations"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-6049","authenticated-orcid":false,"given":"Gary J.","family":"Farkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Solinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apmr.2026.02.498_bib0001","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.spinee.2021.05.014","article-title":"Cardiovascular and metabolic morbidity following spinal cord injury","volume":"21","author":"Peterson","year":"2021","journal-title":"Spine J"},{"key":"10.1016\/j.apmr.2026.02.498_bib0002","article-title":"Associations between obesity and cardiometabolic, physical, and psychosocial health in chronic traumatic spinal cord injury","author":"Brenman","year":"2025","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0003","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/jpm12071088","article-title":"The diagnosis and management of cardiometabolic risk and cardiometabolic syndrome after spinal cord injury","volume":"12","author":"Farkas","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0004","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3390\/jcm14092872","article-title":"Cardiometabolic risk in chronic spinal cord injury: a systematic review with meta-analysis and temporal and geographical trends","volume":"14","author":"Farkas","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0005","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.apmr.2021.09.019","article-title":"Cause of death trends among persons with spinal cord injury in the United States: 1960-2017","volume":"103","author":"DeVivo","year":"2021","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0006","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/10790268.2017.1357104","article-title":"Neurogenic obesity and systemic inflammation following spinal cord injury: a review","volume":"41","author":"Farkas","year":"2018","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46292\/sci20-00067","article-title":"Pathophysiology of neurogenic obesity after spinal cord injury","volume":"27","author":"Gater","year":"2021","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.sc.3100718","article-title":"The changes in human spinal sympathetic preganglionic neurons after spinal cord injury","volume":"37","author":"Krassioukov","year":"1999","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2026.02.498_bib0009","article-title":"Increased symptomatic autonomic dysfunction is associated with greater cardiovascular endothelial dysfunction following spinal cord injury","volume":"25","author":"Pramanik","year":"2025","journal-title":"PM R."},{"key":"10.1016\/j.apmr.2026.02.498_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2023.107110","article-title":"Reasons for meal termination, eating frequency, and typical meal context differ between persons with and without a spinal cord injury","volume":"192","author":"Farkas","year":"2024","journal-title":"Appetite"},{"key":"10.1016\/j.apmr.2026.02.498_bib0011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.46292\/sci24-00028","article-title":"Grocery shopping and eating behaviors differ between persons with and without a spinal cord injury","volume":"31","author":"Donato","year":"2025","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2025.115207","article-title":"Gastrointestinal dysmotility and impaired gut peptide-satiety coupling in men with spinal cord injury","volume":"305","author":"Farkas","year":"2026","journal-title":"Physiol Behav"},{"key":"10.1016\/j.apmr.2026.02.498_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2021.105628","article-title":"Accentuated early postprandial satiety in people with spinal cord injury versus able-bodied controls","volume":"167","author":"Fenton","year":"2021","journal-title":"Appetite"},{"key":"10.1016\/j.apmr.2026.02.498_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.106384","article-title":"A comparison of meal-related appetite, food reward and eating behaviour traits in people with and without spinal cord injury","volume":"181","author":"Fenton","year":"2023","journal-title":"Appetite"},{"key":"10.1016\/j.apmr.2026.02.498_bib0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/WCO.0000000000001206","article-title":"Assessing the efficacy of duration and intensity prescription for physical activity in mitigating cardiometabolic risk after spinal cord injury","volume":"36","author":"Farkas","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.apmr.2026.02.498_bib0016","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/00007256-200434110-00003","article-title":"Exercise recommendations for individuals with spinal cord injury","volume":"34","author":"Jacobs","year":"2004","journal-title":"Sports Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sc.2012.53","article-title":"Exercise participation barrier prevalence and association with exercise participation status in individuals with spinal cord injury","volume":"51","author":"Cowan","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2026.02.498_bib0018","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1310\/sci1802-126","article-title":"Perceived exercise barriers and odds of exercise participation among persons with SCI living in high-income households","volume":"18","author":"Cowan","year":"2012","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0019","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1002\/osp4.784","article-title":"Potential barriers to the use of anti-obesity medications in persons with spinal cord injuries and disorders","volume":"10","author":"LaVela","year":"2024","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.apmr.2026.02.498_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108824","article-title":"GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?","volume":"269","author":"Arredouani","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apmr.2026.02.498_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.apmr.2026.02.498_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154031","article-title":"The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship","volume":"103","author":"Nauck","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.apmr.2026.02.498_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101762","article-title":"Discovery of ecnoglutide \u2013 a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog","volume":"75","author":"Guo","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.apmr.2026.02.498_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0026","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0027","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity \u2013 a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0028","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0029","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.apmr.2026.02.498_bib0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.apmr.2026.02.498_bib0031","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.apmr.2026.02.498_bib0032","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes Facts"},{"key":"10.1016\/j.apmr.2026.02.498_bib0033","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/obr.12889","article-title":"Management of overweight and obesity in primary care\u2013a systematic overview of international evidence-based guidelines","volume":"20","author":"Semlitsch","year":"2019","journal-title":"Obes Rev"},{"issue":"25 Suppl 2","key":"10.1016\/j.apmr.2026.02.498_bib0034","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.apmr.2026.02.498_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.apmr.2026.02.498_bib0036","series-title":"Weight change with semaglutide","author":"Little","year":"2023"},{"issue":"Suppl 2","key":"10.1016\/j.apmr.2026.02.498_bib0037","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.apmr.2026.02.498_bib0038","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1152\/japplphysiol.00729.2002","article-title":"Factors influencing body composition in persons with spinal cord injury: a cross-sectional study","volume":"95","author":"Spungen","year":"2003","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.apmr.2026.02.498_bib0039","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sc.2009.33","article-title":"Lowering body mass index cutoffs better identifies obese persons with spinal cord injury","volume":"47","author":"Laughton","year":"2009","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2026.02.498_bib0040","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.apmr.2021.04.022","article-title":"Acute spinal cord injury is associated with prevalent cardiometabolic risk factors","volume":"103","author":"Solinsky","year":"2022","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0041","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/pmrj.12857","article-title":"Cardiometabolic risk profiling during spinal cord injury rehabilitation: a longitudinal analysis from the Swiss Spinal Cord Injury (SwiSCI) cohort","volume":"15","author":"Raguindin","year":"2023","journal-title":"PM R"},{"key":"10.1016\/j.apmr.2026.02.498_bib0042","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/10790268.2018.1511401","article-title":"Identification and management of cardiometabolic risk after spinal cord injury","volume":"42","author":"Nash","year":"2019","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0043","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1017\/S0007114521003822","article-title":"Energy expenditure and nutrient intake after spinal cord injury: a comprehensive review and practical recommendations","volume":"128","author":"Farkas","year":"2022","journal-title":"Br J Nutr"},{"key":"10.1016\/j.apmr.2026.02.498_bib0044","article-title":"Potential of social engagement for overcoming barriers to physical activity in individuals with spinal cord injury","volume":"10","author":"Canori","year":"2023","journal-title":"J Rehabil Assist Technol Eng"},{"key":"10.1016\/j.apmr.2026.02.498_bib0045","article-title":"Perceived barriers to leisure-time physical activity among physically active individuals with spinal cord injury","volume":"6","author":"Watson","year":"2024","journal-title":"Arch Rehabil Res Clin Transl"},{"key":"10.1016\/j.apmr.2026.02.498_bib0046","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/10790268.2015.1123845","article-title":"Problematic secondary health conditions among adults with spinal cord injury and its impact on social participation and daily life","volume":"39","author":"Piatt","year":"2016","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0047","doi-asserted-by":"crossref","first-page":"68","DOI":"10.46292\/sci20-00061","article-title":"Upper extremity overuse injuries and obesity after spinal cord injury","volume":"27","author":"Vives Alvarado","year":"2021","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0048","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41394-022-00539-1","article-title":"Qualitative analysis of perceived motivators and barriers to exercise in individuals with spinal cord injury enrolled in an exercise study","volume":"8","author":"Tiu","year":"2022","journal-title":"Spinal Cord Ser Cases"},{"key":"10.1016\/j.apmr.2026.02.498_bib0049","doi-asserted-by":"crossref","first-page":"135","DOI":"10.46292\/sci20-00025","article-title":"Barriers and facilitators to lifestyle intervention engagement and weight loss in people living with spinal cord injury","volume":"27","author":"Betts","year":"2021","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/rep0000544","article-title":"Nutrition and eating beliefs and behaviors among individuals with spinal cord injuries and disorders: healthy or misconceived?","volume":"70","author":"LaVela","year":"2025","journal-title":"Rehabil Psychol"},{"key":"10.1016\/j.apmr.2026.02.498_bib0051","doi-asserted-by":"crossref","first-page":"109","DOI":"10.46292\/sci20-00058","article-title":"Exercise interventions targeting obesity in persons with spinal cord injury","volume":"27","author":"McMillan","year":"2021","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0052","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ajcn\/77.2.371","article-title":"Differences in resting metabolic rate between paraplegic and able-bodied subjects are explained by differences in body composition","volume":"77","author":"Buchholz","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.apmr.2026.02.498_bib0053","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1210\/jc.2002-020939","article-title":"Intact sympathetic nervous system is required for leptin effects on resting metabolic rate in people with spinal cord injury","volume":"88","author":"Jeon","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apmr.2026.02.498_bib0054","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/ajcn\/68.6.1223","article-title":"Lower daily energy expenditure as measured by a respiratory chamber in subjects with spinal cord injury compared with control subjects","volume":"68","author":"Monroe","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.apmr.2026.02.498_bib0055","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/PHM.0000000000001166","article-title":"Caloric intake relative to total daily energy expenditure using a spinal cord injury-specific correction factor: an analysis by level of injury","volume":"98","author":"Farkas","year":"2019","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0056","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/10790268.2023.2207064","article-title":"Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: a controlled case series","volume":"47","author":"Cirnigliaro","year":"2023","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0057","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41394-025-00699-w","article-title":"Treatment of obesity in spinal cord injury with tirzepatide: a case report","volume":"11","author":"Juszczak","year":"2025","journal-title":"Spinal Cord Ser Cases"},{"key":"10.1016\/j.apmr.2026.02.498_bib0059","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2337\/dsi24-0001","article-title":"A guideline-directed approach to obesity treatment","volume":"37","author":"Chao","year":"2024","journal-title":"Diabetes Spectr"},{"issue":"Supplement_1","key":"10.1016\/j.apmr.2026.02.498_bib0060","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.2337\/dc26-S008","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.apmr.2026.02.498_bib0061","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0062","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/oby.24336","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"33","author":"Mozaffarian","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.apmr.2026.02.498_bib0063","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.therap.2020.02.024","article-title":"Incretin-based drugs and intestinal obstruction: a pharmacovigilance study","volume":"75","author":"Gudin","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.apmr.2026.02.498_bib0064","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.apmr.2026.02.498_bib0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0066","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.apmr.2026.02.498_bib0067","article-title":"Medication-induced gastroparesis: a case report","volume":"9","author":"Kalas","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.apmr.2026.02.498_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.apmr.2026.02.498_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.apmr.2026.02.498_bib0070","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes Pillars"},{"key":"10.1016\/j.apmr.2026.02.498_bib0071","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nut.2017.01.012","article-title":"The excessive caloric intake and micronutrient deficiencies related to obesity after a long-term interdisciplinary therapy","volume":"38","author":"Poli","year":"2017","journal-title":"Nutrition"},{"key":"10.1016\/j.apmr.2026.02.498_bib0072","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.apmr.2026.02.498_bib0073","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: the effects of medically induced weight loss on skeletal muscle","volume":"12","author":"Prado","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.apmr.2026.02.498_bib0074","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.apmr.2026.02.498_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.apmr.2026.02.498_bib0076","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.ijo.0803483","article-title":"Changes in fat-free mass during significant weight loss: a systematic review","volume":"31","author":"Chaston","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.apmr.2026.02.498_bib0077","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13370","article-title":"The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis","volume":"23","author":"Nuijten","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.apmr.2026.02.498_bib0078","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jn\/136.6.1453","article-title":"Bone, body weight, and weight reduction: what are the concerns?","volume":"136","author":"Shapses","year":"2006","journal-title":"J Nutr"},{"key":"10.1016\/j.apmr.2026.02.498_bib0079","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MED.0000000000000087","article-title":"Weight loss and bone mineral density","volume":"21","author":"Hunter","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.apmr.2026.02.498_bib0080","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/jnnp.47.5.564","article-title":"Slimmer\u2019s paralysis\u2013peroneal neuropathy during weight reduction","volume":"47","author":"Sotaniemi","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.apmr.2026.02.498_bib0081","article-title":"The tirzepatide drop: beware of slimmer\u2019s paralysis","volume":"12","author":"Tucker","year":"2024","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.apmr.2026.02.498_bib0082","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.apmr.2026.02.498_bib0083","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0404.2011.01508.x","article-title":"Gastric and small intestinal dysfunction in spinal cord injury patients","volume":"125","author":"Fynne","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.apmr.2026.02.498_bib0084","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/sc.2011.92","article-title":"SmartPill technology provides safe and effective assessment of gastrointestinal function in persons with spinal cord injury","volume":"50","author":"Williams","year":"2012","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2026.02.498_bib0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.46292\/sci20-00031","article-title":"Dietetics after spinal cord injury: current evidence and future perspectives","volume":"27","author":"Farkas","year":"2021","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0086","first-page":"880","article-title":"An examination of dietary intakes and nutritional status of chronic healthy spinal cord injured individuals","volume":"30","author":"Levine","year":"1992","journal-title":"Paraplegia"},{"key":"10.1016\/j.apmr.2026.02.498_bib0087","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1179\/2045772313Y.0000000180","article-title":"Dietary intake and adherence to the 2010 Dietary Guidelines for Americans among individuals with chronic spinal cord injury: a pilot study","volume":"37","author":"Lieberman","year":"2014","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0088","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jand.2018.08.153","article-title":"Baseline dietary intake of individuals with spinal cord injury who are overweight or obese","volume":"119","author":"Silveira","year":"2018","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.apmr.2026.02.498_bib0089","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41393-018-0218-4","article-title":"Nutritional status in chronic spinal cord injury: a systematic review and meta-analysis","volume":"57","author":"Farkas","year":"2019","journal-title":"Spinal Cord"},{"key":"10.1016\/j.apmr.2026.02.498_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pmr.2024.07.002","article-title":"Making the invisible visible: understanding autonomic dysfunctions following spinal cord injury","volume":"36","author":"Rempel","year":"2025","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.apmr.2026.02.498_bib0091","doi-asserted-by":"crossref","DOI":"10.1111\/iwj.14792","article-title":"Effects of alternating pressure patterns on sacral skin blood flow responses in people with spinal cord injury","volume":"21","author":"Pauly","year":"2024","journal-title":"Int Wound J"},{"key":"10.1016\/j.apmr.2026.02.498_bib0092","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/jpm13060966","article-title":"The pathophysiology, identification and management of fracture risk, sublesional osteoporosis and fracture among adults with spinal cord injury","volume":"13","author":"Craven","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.apmr.2026.02.498_bib0093","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.70073","article-title":"The effect of home-based neuromuscular electrical stimulation-resistance training and protein supplementation on lean mass in persons with spinal cord injury: a pilot study","volume":"12","author":"Hoekstra","year":"2024","journal-title":"Physiol Rep"},{"key":"10.1016\/j.apmr.2026.02.498_bib0094","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jelekin.2008.03.002","article-title":"Functional electrical stimulation cycling improves body composition, metabolic and neural factors in persons with spinal cord injury","volume":"19","author":"Griffin","year":"2009","journal-title":"J Electromyogr Kinesiol"},{"key":"10.1016\/j.apmr.2026.02.498_bib0095","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40798-022-00508-w","article-title":"Synergistic effect of increased total protein intake and strength training on muscle strength: a dose-response meta-analysis of randomized controlled trials","volume":"8","author":"Tagawa","year":"2022","journal-title":"Sports Med Open"},{"key":"10.1016\/j.apmr.2026.02.498_bib0096","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/PHM.0b013e318114cb6d","article-title":"Prevalence of depression diagnoses and use of antidepressant medications by veterans with spinal cord injury","volume":"86","author":"Smith","year":"2007","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0097","first-page":"417","article-title":"Superior mesenteric artery syndrome in acute traumatic quadriplegia: case reports and literature review","volume":"72","author":"Roth","year":"1991","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.apmr.2026.02.498_bib0098","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","article-title":"2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Gilbert","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apmr.2026.02.498_bib0099","unstructured":"US Food and Drug Administration. Wegovy (semaglutide) injection. 2025."},{"key":"10.1016\/j.apmr.2026.02.498_bib0101","series-title":"Semaglutide for managing overweight and obesity","year":"2023"},{"key":"10.1016\/j.apmr.2026.02.498_bib0102","series-title":"Liraglutide","author":"Cerillo","year":"2025"},{"key":"10.1016\/j.apmr.2026.02.498_bib0103","unstructured":"US Food and Drug Administration. Saxenda (liraglutide) injection. 2025."},{"key":"10.1016\/j.apmr.2026.02.498_bib0104","author":"Novo Nordisk"},{"key":"10.1016\/j.apmr.2026.02.498_bib0105","series-title":"Semaglutide","author":"Kommu","year":"2025"},{"key":"10.1016\/j.apmr.2026.02.498_bib0106","author":"Lilly"},{"key":"10.1016\/j.apmr.2026.02.498_bib0107","series-title":"Tirzepatide","author":"Farzam","year":"2025"},{"key":"10.1016\/j.apmr.2026.02.498_bib0108","unstructured":"US Food and Drug Administration. Zepbound (tirzepatide) Injection. 2025."},{"key":"10.1016\/j.apmr.2026.02.498_bib0109","author":"Lilly"}],"container-title":["Archives of Physical Medicine and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999326005800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003999326005800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:45:48Z","timestamp":1786023948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003999326005800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":107,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0003999326005800"],"URL":"https:\/\/doi.org\/10.1016\/j.apmr.2026.02.498","relation":{},"ISSN":["0003-9993"],"issn-type":[{"value":"0003-9993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Receptor Agonists as Pharmacologic Treatment for Obesity After Spinal Cord Injury: Clinical Considerations","name":"articletitle","label":"Article Title"},{"value":"Archives of Physical Medicine and Rehabilitation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apmr.2026.02.498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Congress of Rehabilitation Medicine","name":"copyright","label":"Copyright"}]}}